Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Develo... (ounced co-development partners. ...)

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

Date:6/1/2009

ounced co-development partners.

"Access is extremely pleased with the clinical results to date, which we believe reflect that we have a significant DACH platinum drug candidate with a safety profile superior to commercially available platinum therapies," stated Jeffrey Davis, President & CEO. "Our partners in the Far East, both Aosaikang Medicinal Group (ASK) in Nanjing, China and JCOM, in Seoul, Korea, are making great progress on manufacturing scale-up and in putting the regulatory process in place, and we are working with them diligently on the design and future management of their clinical trials. Access is in discussion with a number of potential North American and European partners for co-development of ProLindac, and to assist in marketing, when approved."

"We are very pleased with the ProLindac trial results to date which has been in over 50 patients in two trials; we saw significant DACH platinum activity and efficacy in patients at the highest dose levels which is very encouraging given that this study involved monotherapy in a heavily pretreated patient population that typically only respond to an aggressive drug combination," commented Dr. David Nowotnik, Access' Senior Vice President R&D.

The recent Phase 2 study explored three different dose levels and two dosing regimens of ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy anticancer activity and safety of ProLindac. Of patients eligible for evaluation according to standard RECIST criteria, clinically-meaningful disease stabilization was achieved in 42% of all patients, and 66% of all patients in the higher dose groups. Sustained and significant reductions in Ca-125, the established specific serum marker for ovarian cancer, were also observed in several patients.

Access is currently in discus
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
2. LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide
3. Security Officers Who Protect Kaiser Hospitals Rally With Community Supporters for Access to Affordable Healthcare
4. Lingraphica introduces the SmallTalk mobile accessory for aphasia
5. Physical Therapists Advocate for Access to Rehabilitative Services on Capitol Hill
6. Communities Containing More Alcohol Outlets Show Increased Underage Alcohol Access
7. Viant Expands Relationship With HMA for Improved Healthcare Access in AZ
8. Access to environmental research in developing nations grown to 1,500 institutions
9. AccessRx.com Provides Same-Day Shipping for Tamiflu, an Effective Treatment for Swine Flu
10. Access to care leads Americans priorities in first-ever public study of health value
11. Access to Care Leads Americans Priorities in First-Ever Public Study of Health Value

Post Your Comments:

(Date:5/22/2013)... SAN FRANCISCO Researchers in genomic health disparities from ... the Stanford University School of Medicine have teamed up ... Conference to Eliminate Health Disparities in Genomic Medicine." ... role of nonprofits, business and government to reduce these ... of the United States, individuals within underserved groups continue ...

(Date:5/22/2013)... , , WEDNESDAY, May 22 (HealthDay News) -- Migraines and ... but new research indicates the combination of the two ... smaller brain. , , Already aware that people with ... to determine if having both conditions together affected total ... percent -- isn,t alarming, study authors said, but needs ...

(Date:5/22/2013)... York, US (PRWEB) May 22, 2013 ... Awards , Read the press release here: http://bit.ly/13DkFfk ... Merrill DataSite® was named “Information Management Product/Service of the ... held in March at The Colony Hotel in Palm ... secure virtual data room (VDR) solution that ...

(Date:5/22/2013)... Recent tragedies including the Oklahoma tornado, ... in Newtown, Connecticut all resulted in serious, and ... medical practitioners train to respond to both adult ... for Children (EMSC) Program specifically provides instruction, education ... patients. It is estimated 30 million children will ...

(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...

Breaking Medicine News(10 mins):Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 3 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3 Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2 Health News:How To "Make Your Own Healthy Energy Bars" 2

[0] Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year”[0] When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care [0] How To "Make Your Own Healthy Energy Bars"

... NEW YORK, Sept. 3 As millions of teens head back ... , , Teens are at a greater risk of ... largely to lack of experience. Many of those crashes could be avoided ... group that produces free driver education programs. , , ...

... This release is available in German . ... weeks before surgery can halve their risk of poor wound ... Efficiency in Health Care (IQWiG) concludes in information published on ... of stress is not easy "It is not easy ...

... 3, 2009) National Cancer Institute (NCI) has renewed ... grant in prevention, diagnosis and treatment of ovarian cancer, ... and the University of Pennsylvania. First approved in ... Fox Chase-Penn Ovarian SPORE. "The SPORE program has always ...

... , , , NEW YORK, Sept. ... in its catalogue. , , U.S. Markets ... http://www.reportlinker.com/p0109210/US-Markets-for-Addiction-and-Substance-Abuse-Treatment.html , , ... , This BCC Research report details the complicated world ...

... , NEW YORK, Sept. 3 , , ... catalogue. , , Healthcare Information Technology ... This Report: , , , ... care IT technologies , Forecasts trends and sales ...

... , , , LANSING, Mich., ... Michigan is launching a television awareness campaign this holiday weekend ... , "Mental illness can be treated and most ... the support of their family and friends," said Sherri Solomon, Executive ...

Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation It pays to quit smoking before surgery NCI renews Fox Chase / Penn Ovarian Cancer 'SPORE' grant for a third 5-year term Reportlinker Adds U.S. Markets for Addiction and Substance Abuse Treatment Report Reportlinker Adds Healthcare Information Technology Report National Alliance on Mental Illness (NAMI Michigan) Launches TV Awareness Campaign

(Date:5/22/2013)... 22, 2013 STEPh, Inc., a full service ... of their web site ( http://www.stephreports.com ) ... About STEPh Reports STEPh Reports are ... Each STEPh Report assesses the competitive landscape by ... year, company, and specific key issues. STEPh Reports are ...

(Date:5/22/2013)... May 22, 2013 Upsher-Smith Laboratories, ... of its global Phase III clinical trial ... program for the management of epilepsy in ... USL255 is specifically engineered to provide convenient ... blood levels observed with currently available treatment ...

(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter. The Facebook homepage ... Says CEO Bruce J. ...

Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Medifirst Solutions, Inc. Announces Update To Shareholders 2

[0] Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site [0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Medifirst Solutions, Inc. Announces Update To Shareholders

... CARSON CITY, Nev., Dec. 21, 2011 Denali Concrete ... has commenced patient enrollment for a phase 3 clinical ... administered orally, in patients with moderate-to-severe Dry Eye Syndrome. ... States, Europe and Israel. The randomized, double-masked clinical trial ...

... and BEDMINSTER, N.J., Dec. 20, 2011 QRxPharma Limited (ASX: QRX ... of Intent (LOI) with Actavis Inc. for the formation of ... acute pain marketplace. MoxDuo IR is a patented ... Inc. is a subsidiary of Actavis Group, hf a privately ...

Cached Medicine Technology:Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study 2 QRxPharma Announces Strategic Partnership with Actavis 2 QRxPharma Announces Strategic Partnership with Actavis 3 QRxPharma Announces Strategic Partnership with Actavis 4 QRxPharma Announces Strategic Partnership with Actavis 5

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study QRxPharma Announces Strategic Partnership with Actavis

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Promazine, Urine Prolactin Macroadenoma Prograf Proloprim